Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction

Conditions:Breast Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Age Range:18 - Any
Start Date:March 23, 2017
End Date:November 1, 2022
Contact:The Ohio State University Comprehensive Cancer Center

Use our guide to learn which trials are right for you!

Multi-institution Phase II Trial of Intraoperative Electron Beam Radiotherapy Boost at the Time of Breast Conserving Surgery With Oncoplastic Reconstruction in Women With Early-Stage Breast Cancer

This phase II trial studies the side effects of intraoperative electron beam radiotherapy
boost and to see how well it works in treating patients with stage I-II breast cancer
undergoing surgery with reconstruction. Giving a single dose of electron beam radiation to
the tumor cavity during the breast surgery before reconstruction may be a better way to kill
tumor cells and shrink tumors.


I. To determine the rate of grade 3 breast fibrosis at 1 year in women undergoing lumpectomy
with oncoplastic reconstruction and immediate intraoperative electron radiotherapy boost
followed by adjuvant whole breast radiotherapy.


I. To determine the rate of 5 year ipsilateral breast tumor recurrence rate. II. To determine
the change in self-reported cosmesis using the Breast Cancer Treatment Outcome Scale (BCTOS)

III. To evaluate physician-reported cosmetic outcomes using the 4-point Harvard Cosmesis
Scale and digital photographs.


Patients undergo standard of care lumpectomy and then undergo 1 fraction of intraoperative
electron beam radiation therapy (IOERT) boost to the lumpectomy cavity. Patients then undergo
standard of care oncoplastic reconstruction and whole breast radiation therapy.

After completion of study treatment, patients are followed up at 1 month, 6 months, 1 year,
and every year thereafter for 5 years.

Inclusion Criteria:

- Pathologically proven diagnosis of breast cancer

- Clinical node negative stage I (T1N0) or stage II (T2N0) breast cancer

- Preoperative ultrasound of the axilla with biopsy of suspicious nodes is
recommended as clinically indicated per the discretion of the treating physician

- Appropriate stage for protocol entry including no clinical evidence for distant
metastases based upon the following minimum diagnostic workup

- History/physical examination, documentation of weight and Zubrod performance status
0-2 within 28 days prior to study entry

- Right and left mammography within 90 days of diagnostic biopsy establishing diagnosis

- Absolute neutrophil count > 1800 cells/cubic mm

- Platelets >= 75,000 cells/cubic mm

- Hemoglobin >= 8 g/dL

- Women of childbearing potential must have a negative urine or serum pregnancy test
within 14 days of study entry

- Women of childbearing potential must be non-pregnant and non-lactating and willing to
use medically acceptable form of contraception during radiation therapy

- Patients must provide study specific informed consent prior to study entry

Exclusion Criteria:

- Clinical T4, N2 or N3, M1 pathologic stages III or IV breast cancer

- Prior invasive non-breast malignancy (except non-melanoma skin cancer, carcinoma in
situ of the cervix) unless disease free for a minimum of 3 yrs prior to study entry

- Prior invasive or in-situ carcinoma of the breast (prior lobular breast carcinoma in
situ [LCIS] is eligible)

- Two or more cancers not resectable through a single lumpectomy incision

- Bilateral breast cancer

- Ductal breast carcinoma in situ (DCIS) only

- Non-epithelial breast malignancies such as sarcoma/lymphoma

- Male breast cancer

- Paget's disease of the nipple

- Prior radiotherapy to the breast or prior radiation to the region of the ipsilateral
breast that would result in overlap of radiation fields

- Pregnancy or women of childbearing potential who are sexually active and not
willing/able to use medically acceptable forms of contraception

- Active systemic lupus, erythematosus, or any history of scleroderma, dermatomyositis
with active rash

- Medical, psychiatric or other condition that would prevent the patient from receiving
the protocol therapy or providing informed consent
We found this trial at
Chapel Hill, North Carolina 27599
(919) 962-2211
Principal Investigator: Gaorav Gupta, MD, PhD
Phone: 984-974-8744
Univ of North Carolina Carolina’s vibrant people and programs attest to the University’s long-standing place...
Chapel Hill, NC
Click here to add this to my saved trials
3900 W Avera Drive
Sioux Falls, South Dakota 57108
(605) 322-4700
Principal Investigator: Kyle Arneson, MD
Phone: 605-322-3095
Avera Cancer Institute Avera, the health ministry of the Benedictine and Presentation Sisters, is a...
Sioux Falls, SD
Click here to add this to my saved trials
Columbus, Ohio 43210
Principal Investigator: Jose G. Bazan
Phone: 614-688-7371
Columbus, OH
Click here to add this to my saved trials